Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
FXI vs IBB: how they differ
FXI and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
iShares China Large-Cap ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, FXI and IBB hold 0% of their money in the same securities at the same weight.
| Only in FXI | Only in IBB |
|---|---|
| Alibaba Group Holding Limited 8.66% | Vertex Pharmaceuticals, Inc. 8.09% |
| CHINA CONSTRUCTION BANK CORPORATION 8.25% | Amgen, Inc. 7.84% |
| Tencent Holdings Limited 7.72% | Gilead Sciences, Inc. 6.85% |
| INDUSTRIAL AND COMMERCIAL BANK OF CHINA 6.02% | Regeneron Pharmaceuticals, Inc. 4.91% |
| XIAOMI CORPORATION 5.41% | Argenx SE 3.76% |
| MEITUAN 4.79% | Alnylam Pharmaceuticals, Inc. 3.12% |
| Ping An Insurance (Group) Company of Chi 4.41% | Natera, Inc. 2.89% |
| BYD COMPANY LIMITED 4.09% | Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| FXI iShares China Large-Cap ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | China Large-Cap | Biotechnology |
| Total return, 1 year | −13.8% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −31.3 pts | +24.0 pts |
| Expense ratio | 0.73% | 0.44% |
| Already in the S&P 500 | 0.0% | 35.6% |
| Holdings | 52 | 248 |
FXI in plain words
FXI is an index equity fund tracking the China Large-Cap. Over the year to Sep 11, 2026 it returned −13.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.73% a year. By its holdings filed for Apr 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 52 positions, with the top ten at 56.6%. It sat 28.5% below its high of Feb 17, 2021 on Sep 11, 2026.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, FXI or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, FXI returned −13.8% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, FXI or IBB?
- FXI charges 0.73% a year and IBB charges 0.44%, so IBB is cheaper. Fees come from each fund's prospectus.
- How much do FXI and IBB overlap with the S&P 500?
- By their latest filed holdings, 0% of FXI and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, FXI against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/FXI-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources